Birinapant (BioDeep_00000687416)

   


代谢物信息卡片


Birinapant

化学式: C42H56F2N8O6 (806.4290659999999)
中文名称: 比瑞那帕
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCC(C(=O)N1CC(CC1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)CC6CC(CN6C(=O)C(CC)NC(=O)C(C)NC)O)O)NC(=O)C(C)NC
InChI: InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1

描述信息

C274 - Antineoplastic Agent > C129839 - Apoptotic Pathway-targeting Antineoplastic Agent

同义名列表

1 个代谢物同义名

Birinapant



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Weiyan Zhang, Shenghuan Sun, Wenyuan Zhu, Delan Meng, Weiyi Hu, Siqi Yang, Mingjie Gao, Pengju Yao, Yuhao Wang, Qingsong Wang, Jianguo Ji. Birinapant Reshapes the Tumor Immunopeptidome and Enhances Antigen Presentation. International journal of molecular sciences. 2024 Mar; 25(7):. doi: 10.3390/ijms25073660. [PMID: 38612472]
  • Kiran Bharat Lokhande, Sayali Doiphode, Renu Vyas, K Venkateswara Swamy. Molecular docking and simulation studies on SARS-CoV-2 Mpro reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19. Journal of biomolecular structure & dynamics. 2021 11; 39(18):7294-7305. doi: 10.1080/07391102.2020.1805019. [PMID: 32815481]
  • David Cerna, Bora Lim, Yusuf Adelabu, Stephen Yoo, Donna Carter, Ahmed Fahim, Yasuhiro Mitsuuchi, Beverly A Teicher, Eric Bernhard, C Norman Coleman, Naoko Takebe, Mansoor M Ahmed. SMAC Mimetic/IAP Inhibitor Birinapant Enhances Radiosensitivity of Glioblastoma Multiforme. Radiation research. 2021 06; 195(6):549-560. doi: 10.1667/rade-20-00171.1. [PMID: 33826739]
  • Manuela Hugle, Sebastian Czaplinski, Karoline Habermann, Meike Vogler, Simone Fulda. Identification of Smac mimetics as novel substrates for p-glycoprotein. Cancer letters. 2019 01; 440-441(?):126-134. doi: 10.1016/j.canlet.2018.10.001. [PMID: 30312727]
  • Hongxiang Liu, Rui Liao, Kun He, Xiwen Zhu, Peizhi Li, Jianping Gong. The SMAC mimetic birinapant attenuates lipopolysaccharide-induced liver injury by inhibiting the tumor necrosis factor receptor-associated factor 3 degradation in Kupffer cells. Immunology letters. 2017 05; 185(?):79-83. doi: 10.1016/j.imlet.2017.02.016. [PMID: 28286228]
  • Anne M Noonan, Kristen P Bunch, Jin-Qiu Chen, Michelle A Herrmann, Jung-Min Lee, Elise C Kohn, Ciara C O'Sullivan, Elizabeth Jordan, Nicole Houston, Naoko Takebe, Robert J Kinders, Liang Cao, Cody J Peer, W Douglas Figg, Christina M Annunziata. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer. 2016 Feb; 122(4):588-597. doi: 10.1002/cncr.29783. [PMID: 26566079]
  • Ravi K Amaravadi, Russell J Schilder, Lainie P Martin, Myron Levin, Martin A Graham, David E Weng, Alex A Adjei. A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. Molecular cancer therapeutics. 2015 Nov; 14(11):2569-75. doi: 10.1158/1535-7163.mct-15-0475. [PMID: 26333381]
  • Gregor Ebert, Cody Allison, Simon Preston, James Cooney, Jesse G Toe, Michael D Stutz, Samar Ojaimi, Nikola Baschuk, Ueli Nachbur, Joseph Torresi, John Silke, C Glenn Begley, Marc Pellegrini. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 2015 May; 112(18):5803-8. doi: 10.1073/pnas.1502400112. [PMID: 25902530]